FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer
Stephanie Annett(Royal College of Surgeons in Ireland), Tracy Robson(Queen's University Belfast), Anna DeFazio(The University of Sydney), Lana McClements(University of Technology Sydney), Sharon O’Toole(Trinity College Dublin), Fiona Furlong(Queen's University Belfast), John O’Leary(St. James's Hospital), Andrea Marshall(Coventry (United Kingdom)), Mark Bates(Trinity College Dublin), Nermeen Moustafa(Queen's University Belfast), Darran P. O’Connor, Catherine J. Kennedy(The University of Sydney), Donal J. Brennan(Mater Misericordiae University Hospital), Amy Short(Queen's University Belfast), Alison H. Brand(The University of Sydney), Ciarán Ó’Riain(St. James's Hospital), Anita Yakkundi(Queen's University Belfast), Helen O. McCarthy(Queen's University Belfast), Gillian Moore(Royal College of Surgeons in Ireland), Raghwa Sharma(Royal Prince Alfred Hospital), Sudipto Das(National Cancer Institute), Laura L. Nelson(Queen's University Belfast), Ian Harley(Università Cattolica del Sacro Cuore), W. Glenn McCluggage(Belfast Health and Social Care Trust), Cian M. McCrudden(Queen's University Belfast), Adrien Kissenpfennig(Queen's University Belfast)
Cited by 65
Related Papers
Whole–genome characterization of chemoresistant ovarian cancer
|Nature|2015|1.7k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
|Clinical Cancer Research|2008|1.5k